MiMedx Shares Plunge On U.S. Sales, Marketing Probe
SAN FRANCISCO – Shares of MiMedx Group Inc. plunged late Wednesday after the bioimplant company said U.S. regulators are investigating its sales and marketing practices. MiMedx shares fell 9% to $10.51 on heavy volume. The company said it received a subpoena from the inspector general of the U.S. Department of Health and Human Services related to a civil investigation. Seperately, MiMedx said it is suing Organogenesis Inc., alleging the company interfered with contracts MiMedx had with the Veterans Administration. During Wednesday's regular session, MiMedx shares closed up 4% after the company said late Tuesday it planned to exceed revenue forecasts for the fourth quarter.
Copyright © 2014 MarketWatch, Inc.